ArticleJournal of internal medicine2025

Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with Type 2 diabetes.

Tung-Ying Hung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.